T2 Biosystems - TTOO Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares.
View TTOO analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price objectives for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $35.00. On average, they predict the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 953.3% from the stock's current price.
View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts.

T2 Biosystems' stock was trading at $25.81 at the beginning of 2022. Since then, TTOO stock has decreased by 93.1% and is now trading at $1.7801.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our TTOO earnings forecast.

T2 Biosystems, Inc. (NASDAQ:TTOO) issued its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($4.00) EPS for the quarter, meeting analysts' consensus estimates of ($4.00). The medical equipment provider had revenue of $7.43 million for the quarter. During the same period in the previous year, the business earned ($4.00) EPS.

T2 Biosystems's stock reverse split on Thursday, October 13th 2022. The 1-50 reverse split was announced on Thursday, October 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

T2 Biosystems updated its FY 2022 earnings guidance on Wednesday, November, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $22.00 million-$23.00 million, compared to the consensus revenue estimate of $26.33 million.

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

T2 Biosystems' stock is owned by a number of retail and institutional investors. Top institutional investors include Altium Capital Management LP (40.28%), Gagnon Securities LLC (10.87%), Bank of New York Mellon Corp (7.64%), Jane Street Group LLC (3.51%), Citadel Advisors LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, David B Elsbree, Goldman Sachs & Co Llc, John J Sperzel III, John M Sprague, John Mcdonough, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends.

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TTOO stock can currently be purchased for approximately $1.78.

T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $12.55 million and generates $28.06 million in revenue each year. The medical equipment provider earns $-49,240,000.00 in net income (profit) each year or ($16.45) on an earnings per share basis.

The company employs 182 workers across the globe.

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at ir@t2biosystems.com, or via fax at 781-357-3080.